^
    Back
    Association details:
    Biomarker:PTCH1 mutation
    Cancer:Melanoma
    Drug:Erivedge (vismodegib) (Hedgehog cell-signalling pathway inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

    Excerpt:
    Three patients had PRs to vismodegib (unknown primary cancer, n = 1; squamous skin cancer, n = 1; salivary gland cancer, n = 1); all three patients had PTCH-1–mutated tumors.
    DOI:
    10.1200/JCO.2017.75.3780